The pharmacokinetics and tolerability of selexipag in patients with mild, moderate, or severe liver impairment and in volunteers.

Trial Profile

The pharmacokinetics and tolerability of selexipag in patients with mild, moderate, or severe liver impairment and in volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Apr 2016

At a glance

  • Drugs Selexipag (Primary)
  • Indications Pulmonary hypertension
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 07 Apr 2016 Pooled analysis of 2 trials, including this and another study (see CTP 700238628) were published in the British Journal of Clinical Pharmacology.
    • 13 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top